|
|
SPOT ON
|
|
Good-bye drug safety : reorganization of the German drug regulatory office BfArM and consequences
|
|
|
THERAPY FORM A CRITICAL VIEWPOINT
|
|
Breast cancer: survival benefit of adjuvant trastuzumab (HERCEPTIN) questionable
|
|
|
REVIEW
|
|
Therapy of age-related macular degeneration (II): treatment of neovascular disease
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
NSAID: naproxen new standard and the economic consequences
Trastuzumab (HERCEPTIN) for the trashcan
|
|
|
IN BRIEF
|
|
Rosiglitazone as first line therapy in type II diabetes mellitus?
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Parkinson disease: heart valve disease by dopamine agonists
|
|
|
SIDE EFFECTS
|
|
Failing orgasm with anticonvulsive topiramate (TOPAMAX/-MIGRÄNE)
|
|